Rafael Holdings, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $97.2M
- Price
- $1.81
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.69%
- Volume
- 149.8K
About
Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Quick stats
Shares outstanding52.0M
Computed float30.6M
Float / shares58.8%
Cash runway (months)9.1
Key info
SectorReal Estate
IndustryReal Estate - Services
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001713863
AI Summary
AI-generated1/18
minorbullishboard change
Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage
Ernexa Therapeutics appointed David Polinsky to its Board of Directors, adding 25 years of biotech leadership and capital markets expertise.
Polinsky currently serves as CFO of Rafael Holdings and co-founded Cornerstone Pharmaceuticals, bringing significant experience in corporate strategy and governance.
The company remains on track to submit an IND for its lead asset ERNA-101 in Q3 2026 and initiate a Phase 1 study in Q4 2026.